AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03797664
Drug: CDX-6114
RxNorm normalized name: CDX
DrugBank: Cefadroxil (DB01140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CDX-6114 will be administered as a single, oral dose solution at dose levels of 7.5, 15.0 and 22.5g
Trial: NCT04494659
Drug: Famitinib capsule
RxNorm normalized name: Axitinib
DrugBank: Famitinib (DB11741)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose and co-administrated with Rifampicin capsule
Trial: NCT04494659
Drug: Rifampicin capsule
RxNorm normalized name: rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: repeated doses of Rifampicin capsule
Trial: NCT02171052
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02171052
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00118105
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 130 mg/m\^2, IV, Day 1 of cycles 1,2,3,4
Trial: NCT01506947
Drug: Paricalcitol
RxNorm normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paricalcitol was administered by intravenous bolus. The initial dose was calculated according to the following formula:~\[Paricalcitol (µg) = iPTH (pg/mL) / 80\]. Subsequent doses were determined based on iPTH, calcium and phosphorus levels.
Trial: NCT01506947
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine darbepoetin alfa use was allowed when transferrin saturation (TSAT) was ≥ 20% and ferritin ≥ 200 μg/L, and hemoglobin level \< 11.5 g/dL. The initial dose was 0.25 to 0.75 µg/kg/week, and the maintenance dose was 0.13 to 0.35 µg/kg/week. Target hemoglobin level was between 10 to 11.5 g/dL.
Trial: NCT01245166
Drug: Acarbose
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose 50 mg, per orem, thrice daily
Trial: NCT01245166
Drug: Metformin/Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metformin HCl 500 mg plus Acarbose 50 mg Tablets, per orem, thrice daily
Trial: NCT00847314
Drug: Testosterone Undeconate (Nebido-R, BAY86-5037)
RxNorm normalized name: Testosterone undeconate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Male patients \> 35yrs in medical practices fulfilling all criteria for documentation.
Trial: NCT02767232
Drug: Recombinant tissue plasminogen activator (rt-PA)
RxNorm normalized name: Tissue plasminogen activator, recombinant
DrugBank: Plasminogen (DB16701)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.
Trial: NCT00446056
Drug: MK0476, montelukast sodium / Duration of Treatment: 4 Weeks
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00446056
Drug: Comparator: ketotifen / Duration of Treatment: 4 Weeks
DrugBank: Ketotifen (DB00920)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00376883
Drug: pamidronate
RxNorm normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00257712
Drug: TH9507 human growth hormone releasing hormone (GHRH)
RxNorm normalized name: Growth hormone (human)
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg subcutaneous injection given daily for 20 weeks
Trial: NCT00282256
Drug: tacrolimus modified release (MR)
RxNorm normalized name: tacrolimus Extended Release Oral Tablet
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00282256
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00940056
Drug: Rate control
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anti-arrhythmic protocol The control group is using a rate-control strategy. All patients keep their anti-arrhythmic/beta-blocker/digoxin medication during the entire follow-up. No attempts are made to rhythm-control the patients, unless subjective symptoms make it necessary.
Trial: NCT00417690
Drug: 4-Aminosalicylic acid
RxNorm normalized name: 4-aminosalicylic acid
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral granules administered as one 4 g packet three times daily for two weeks followed by one 4 g packet two times daily for two weeks
Trial: NCT00479622
Drug: TRU-015
RxNorm normalized name: TRU-015
DrugBank: TRU-015 (DB05580)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 1 = 800 mg Arm 2 = 2000 mg
Trial: NCT00331890
Drug: Citicoline
RxNorm normalized name: Citicoline
DrugBank: Citicoline (DB12153)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1g/12h iv during 3 days and then orally until complete 6 weeks of treatment
Trial: NCT02275416
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04484337
Drug: Cabotegravir sodium (Oral Lead In)
RxNorm normalized name: cabotegravir sodium
DrugBank: Cabotegravir (DB11751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CAB will be available as 30 mg tablets for oral administration.
Trial: NCT01513096
Drug: itopride
RxNorm normalized name: itopride
DrugBank: Itopride (DB04924)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: itopride, 10mg, twice per day, for 1 day
Trial: NCT04484337
Drug: Cabotegravir 400 mg/mL
DrugBank: Cabotegravir (DB11751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CAB 400 mg/mL will be available for administration by IM injection or SC Injection.
Trial: NCT04484337
Drug: Cabotegravir 200 mg/mL
RxNorm normalized name: cabotegravir 200 MG/ML
DrugBank: Cabotegravir (DB11751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CAB 200 mg/mL will be available for administration by IM injection or SC Injection.
Trial: NCT04484337
Drug: Recombinant human hyaluronidase PH20 (rHuPH20)
RxNorm normalized name: PEGylated recombinant human hyaluronidase PH20
DrugBank: Hyaluronidase (ovine) (DB00070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuPH20 will be available for administration by SC Injection
Trial: NCT00493571
Drug: Gimatecan
RxNorm normalized name: Gimatecan
DrugBank: Gimatecan (DB06721)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose: 0.6 mg capsules administered orally once daily.
Trial: NCT00337571
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets, Oral, once daily, 8 weeks
Trial: NCT03193866
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Comparisons of efficacy and safety between rituximab and all other frequently used immunomodulating drugs against multiple sclerosis
Trial: NCT03856970
Drug: Glyburide
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg tablets for oral administration
Trial: NCT03856970
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25 mg tablets for oral administration
Trial: NCT06546215
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administer a single-dose (0.25mg) of either the reference or the test formulation of digoxin tablets.
Trial: NCT01569451
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15
Trial: NCT01569451
Drug: Glatiramer Acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg injected subcutaneously daily
Trial: NCT02386033
Drug: Atorvastatin (ATV)
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After SRP, ATV gel was delivered subgingivally into the pocket
Trial: NCT00861445
Drug: SPM927/Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage 400mg/day, intake in the morning and in the evening, intake for 10 weeks
Trial: NCT02296073
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: midazolam 3～5μg/kg•min for maintenance of sedation.
Trial: NCT02296073
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine 0.5μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
Trial: NCT02296073
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine 0.25μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
Trial: NCT01952249
Drug: Demcizumab
RxNorm normalized name: Demcizumab
DrugBank: Demcizumab (DB12734)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered intravenously
Trial: NCT01952249
Drug: Taxol
RxNorm normalized name: Taxol
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: administered intravenously
Trial: NCT02296073
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine 0.2～1.4μg/(kg.h) for maintenance of sedation；
Trial: NCT00092807
Drug: MK0653, ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00023946
Drug: ixabepilone
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02326051
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously once positive pregnancy test is established and the therapy will continue until termination of pregnancy
Trial: NCT02326051
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously after sonographic confirmation of fetal cardiac pulsation and the therapy will continue until termination of pregnancy
Trial: NCT04662892
Drug: Pegfilgrastim-Cbqv
RxNorm normalized name: pegfilgrastim-cbqv
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Date, Dose, and cycle for subjects who received Udenyca will be recorded. Other FN prophylaxis such as Neulasta, or other pegfilgrastim biosimilars will be collected.
Trial: NCT05946148
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin 10mg daily, as add-on to previous treatment regimen.
Trial: NCT05946148
Drug: Dulaglutide
RxNorm normalized name: DULAGLUTIDE
DrugBank: Dulaglutide (DB09045)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dulaglutide 1.5mg weekly, as add-on to previous treatment regimen
Trial: NCT05946148
Drug: Control Rx
RxNorm normalized name: Control Rx
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Optimal anti-diabetic treatment excluding agents of the GLP1-ras or SGLT2-is families.
Trial: NCT00469625
Drug: paricalcitol (initial dose 1 mcg orally per day)
RxNorm normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00946257
Drug: Otelixizumab
RxNorm normalized name: Otelixizumab
DrugBank: Otelixizumab (DB05496)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A humanized, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb) directed against the ε domain of the human lymphocyte antigen CD3.
Trial: NCT05532878
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban 2.5 mg daily
Trial: NCT02207608
Drug: Hyaluronic Acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Add hyaluronic acid to BCG Treatment
Trial: NCT02207608
Drug: BCG (Immucist®)
RxNorm normalized name: Tice BCG Topical Product
DrugBank: Bacillus calmette-guerin substrain danish 1331 live antigen (DB12386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual BCG treatment
Trial: NCT03353220
Drug: Belviq
RxNorm normalized name: Belviq
DrugBank: Lorcaserin (DB04871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Belviq is an oral drug
Trial: NCT02279953
Drug: Vortioxetine 10-20 mg
RxNorm normalized name: vortioxetine 20 MG
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02279953
Drug: SSRI
RxNorm normalized name: SSRI - Selective serotonin re-uptake inhibitor
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: escitalopram, citalopram or sertraline
Trial: NCT01531205
Drug: Cabazitaxel
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous treatment with Cabazitaxel 25 mg/m\^2 is given on day 1 every 21 days. A cycle of chemotherapy will be defined as 21 days. A total of four cycles of combination therapy are planned for a total duration of 12 weeks (before surgery), starting within 3 weeks of protocol entry, to be given concurrent with hormone therapy.
Trial: NCT01531205
Drug: Neoadjuvant Treatment - Hormonal Therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatment will be given on an outpatient basis. Treatment should start within 3 weeks of protocol entry. All patients will receive androgen ablation with LHRH agonist therapy in conjunction with the 4 cycles of Cabazitaxel for neoadjuvant chemohormonal therapy. Androgen ablative therapy will be discontinued before surgery. A course of bicalutamide 50 mg daily orally for 14-21 days is recommended for patients starting LHRH agonist therapy and suspected to be at risk for tumor flare, e.g., significant obstructive urinary symptoms and will be optional in other patients.
Trial: NCT01531205
Drug: Neoadjuvant Treatment - Cabazitaxel
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatment will be given on an outpatient basis and should start within 3 weeks of protocol entry. Intravenous treatment with Cabazitaxel is given on Day 1 every 3 weeks. A cycle of combination therapy will be defined as 3 weeks. A total of 4 cycles of combination therapy are planned before surgery for a total duration of 12 weeks.~Cabazitaxel will be administered before surgery by one-hourly infusions via central or peripheral intravenous access at a dose of 25 mg/m\^2 as a one hour intravenous infusion in combination with oral prednisone 10 mg administered daily throughout Cabazitaxel treatment. It is advised that all patients receiving Cabazitaxel have a reliable form of venous access, e.g., central venous catheter to ensure their ability to receive therapy without undue delay.
Trial: NCT00959751
Drug: NXN-188
RxNorm normalized name: NXN-188
DrugBank: NXN-188 (DB06096)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg capsules, 600 mg, PRN
Trial: NCT01089647
Drug: budesonide and montelukast
RxNorm normalized name: formoterol and budesonide
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: budesonide aqua nasal spray 1 spray each nostril bid for 12 weeks Montelukast pill 10 mg po daily for 12 weeks
Trial: NCT03218501
Drug: SK-1405 high dose
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SK-1405 high dose is to be administered orally once daily for 2 weeks
Trial: NCT03218501
Drug: SK-1405 low dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: SK-1405 low dose is to be administered orally once daily for 2 weeks
Trial: NCT00498550
Drug: Clozapine
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine up to 550mg per day
Trial: NCT03861039
Drug: Tirzepatide
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04085770
Drug: Alfacalcidol 1 MCG Oral Capsule
RxNorm normalized name: alfacalcidol 1 MCG Oral Capsule
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mcg of oral Bone Care© soft gelatin capsules once daily with food starting from the day of admission till the end of hospital stay
Trial: NCT02124174
Drug: Vidaza and Valproic Acid
RxNorm normalized name: Vidaza
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Days 1-5: 5-Azacytidine 40 mg/m\^2 daily Days 1-5: +Valproic acid 15 mg/kg daily Days 6-28: Valproic acid 15 mg/kg daily~\*treatments will be repeated on the same days of each cycle for up to 4 total cycles. Each cycle will consist of 28 days.
Trial: NCT01566370
Drug: Zonisamide
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: titration of dose to 500mg oral, daily, over 8 weeks, then 6 weeks of treatment at that dose
Trial: NCT00362232
Drug: Rivaroxaban (Xarelto, BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban (Xarelto, BAY59-7939) 10 mg tablet administered once daily (od) in the evening.
Trial: NCT00362232
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syringes of enoxaparin active substance 30 mg twice a day administered once in the morning and once in the evening.
Trial: NCT00362232
Drug: Placebo: tablet of Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo tablet of rivaroxaban administered once daily in the evening.
Trial: NCT00362232
Drug: Placebo: syringes of Enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo syringes of enoxaparin twice a day (bid) administered once in the morning and once in the evening.
Trial: NCT00000209
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03890406
Drug: Rocuronium: PTC(Post-tetanic count) 1~2
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deep neuromuscular blockade will be maintained using continuous infusion of rocuronium.
Trial: NCT03890406
Drug: Rocuronium: TOF(Train-of-four) 1~2
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate neuromuscular blockade will be maintained using continuous infusion of rocuronium.
Trial: NCT01581775
Drug: Divalproex Sodium
RxNorm normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Divalproex Sodium ER Tablets, 500 mg
Trial: NCT03531359
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administration of midazolam oral or rectal 30 minutes to one hour prior to transfer to the theater.
Trial: NCT02388919
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic dosage, take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.
Trial: NCT04670679
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered via intravenous infusion
Trial: NCT04670679
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered via intravenous infusion
Trial: NCT03620669
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab 1500mg q4W until progression or unacceptable toxicity
Trial: NCT01933724
Drug: 5 mg prednisone
RxNorm normalized name: prednisone 5 MG
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to take 5 mg per day of prednisone for a 6 month period.
Trial: NCT01933724
Drug: 0 mg prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to taper their prednisone dose to no prednisone for a 6 month period.
Trial: NCT01499407
Drug: Abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01898078
Drug: Alisertib
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib ECT
Trial: NCT03653741
Drug: Perampanel 6 MG
RxNorm normalized name: perampanel 6 MG
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perampanel is a drug approved and marketed in the USA for the treatment of epilepsy to prevent recurrent seizures. In a previous study, healthy volunteers have tolerated a single dose of perampanel at 6 mg quite well.
Trial: NCT00394056
Drug: Vestipitant
RxNorm normalized name: Vestipitant
DrugBank: Vestipitant (DB11949)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NK1 receptor antagonist
Trial: NCT00394056
Drug: Vestipitant + Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NK1 receptor antagonist and SSRI
Trial: NCT02212067
Drug: semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.